Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV, open-label, randomized study to compare the efficacy and safety of Epivir/Ziagen [lamivudine/abacavir]/Zerit [stavudine] (3TC/ABC/d4T) versus Epivir/Ziagen/Sustiva [efavirenz] (3TC/ABC/EFV) versus Epivir/Ziagen/Agenerase/Norvir [amprenavir/ritonavir](3TC/ABC/APV/RTV) for 96 weeks in the treatment of HIV-1 infected subjects who are antiretroviral therapy naive

Next Previous
X
Search
Trial Profile

A phase IV, open-label, randomized study to compare the efficacy and safety of Epivir/Ziagen [lamivudine/abacavir]/Zerit [stavudine] (3TC/ABC/d4T) versus Epivir/Ziagen/Sustiva [efavirenz] (3TC/ABC/EFV) versus Epivir/Ziagen/Agenerase/Norvir [amprenavir/ritonavir](3TC/ABC/APV/RTV) for 96 weeks in the treatment of HIV-1 infected subjects who are antiretroviral therapy naive

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lamivudine/abacavir (Primary) ; Amprenavir/ritonavir; Efavirenz; Stavudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top